Payment overview · 2025
General Payments
$500.88
20 reported records · 11 companies
Healthcare provider profile · identity verified
Gary T Roome, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BURTON, MI · NPI 1376534396
Verified facts
What the public records show
CMS Open Payments records show Gary T Roome, MD received $500.88 in general payments during 2025 across 20 reported records.
Novo Nordisk Inc accounted for 16.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $83.89 | 16.8% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $83.57 | 16.7% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $72.61 | 14.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $72.39 | 14.4% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $39.02 | 7.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $33.28 | 6.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $30.75 | 6.1% | 2 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $24.71 | 4.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.82 | 4.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $21.67 | 4.3% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.17 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $500.88 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $83.89 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $83.89 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $83.57 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $72.61 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $72.39 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $39.02 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $33.28 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $33.28 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $30.75 | 2 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $24.71 | 1 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $24.71 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $22.82 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.67 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 169 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
42 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
169 | 56 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 755 | 196 |
| Amlodipine Besylate | Amlodipine Besylate | 394 | 118 |
| Lisinopril | Lisinopril | 393 | 113 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 376 | 121 |
| Gabapentin | Gabapentin | 351 | 75 |
| Levothyroxine Sodium | Levothyroxine Sodium | 329 | 80 |
| Metoprolol Succinate | Metoprolol Succinate | 258 | 62 |
| Omeprazole | Omeprazole | 226 | 72 |
| Metformin Hcl | Metformin Hcl | 224 | 63 |
| Famotidine | Famotidine | 206 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 190 | 61 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 169 | 56 |
| Ventolin Hfa | Albuterol Sulfate | 156 | 59 |
| Furosemide | Furosemide | 149 | 37 |
| Ezetimibe | Ezetimibe | 148 | 48 |
| Montelukast Sodium | Montelukast Sodium | 147 | 44 |
| Hydralazine Hcl | Hydralazine Hcl | 143 | 40 |
| Azithromycin | Azithromycin | 137 | 85 |
| Tamsulosin Hcl | Tamsulosin Hcl | 136 | 38 |
| Trazodone Hcl | Trazodone Hcl | 117 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 111 | 38 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 110 | 32 |
| Mirtazapine | Mirtazapine | 107 | 25 |
| Losartan Potassium | Losartan Potassium | 103 | 30 |
| Prednisone | Prednisone | 101 | 55 |
| Lamotrigine | Lamotrigine | 94 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 91 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 88 | 19 |
| Potassium Chloride | Potassium Chloride | 83 | 27 |
| Allopurinol | Allopurinol | 82 | 23 |
| Eliquis | Apixaban | 82 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 76 | 22 |
| Pregabalin | Pregabalin | 76 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 74 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 72 | 13 |
| Buspirone Hcl | Buspirone Hcl | 69 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 68 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 14 |
| Spironolactone | Spironolactone | 57 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 56 | 24 |
| Clonazepam | Clonazepam | 54 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 50 | suppressed |
| Carvedilol | Carvedilol | 49 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 49 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 48 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 47 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 47 | suppressed |
| Aripiprazole | Aripiprazole | 45 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 16 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 43 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 42 | 16 |
| Divalproex Sodium | Divalproex Sodium | 39 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 39 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 38 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 37 | suppressed |
| Mupirocin | Mupirocin | 36 | 24 |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 30 | 14 |
| Simvastatin | Simvastatin | 29 | suppressed |
| Clonidine | Clonidine | 27 | suppressed |
| Ibuprofen | Ibuprofen | 27 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Hydrocortisone | Hydrocortisone | 26 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Jardiance | Empagliflozin | 23 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Tradjenta | Linagliptin | 21 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 20 | suppressed |
| Alprazolam | Alprazolam | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 19 | suppressed |
| Brilinta | Ticagrelor | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 13 |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Meloxicam | Meloxicam | 15 | suppressed |
| Paroxetine Er | Paroxetine Hcl | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $500.88 · 20 records | Novo Nordisk Inc | AIRSUPRA, APTIMA, CAPLYTA, Dexcom G6 Transmitter, FANAPT, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, THINPREP 2000 PROCESSOR, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VRAYLAR | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error